MSD’s Keytruda had been undergoing a Phase III trial for treatment of advanced bladder cancer but met its primary endpoint early into the trial.
An increase in drug consumption, government initiatives and a focus on generic drug use are seen as contributing factors to the growth.
FDA accepts supplemental Biologics License Application (sBLA) for Bristol-Myers Squibb’s Opdivo for treatment of bladder cancer.
Success of its ALKS 5461 treatment in a Phase III study for the treatment of major depressive disorder sent shares rocketing as much as 52%.
The pharmaceutical industry and drug pricing have occupied quite a large space in the debates surrounding the next president of the United States...